Evonile Pharma opens Rs 8,847.54 million rights issue

Corporate Actions View source PDF Explain this filing

EVONILE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1720.10

prior close

₹1701.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.3%+2.6% vs sector

On the reaction day the stock moved 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.4

15m

+0.7

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3pendingpending-0.3+2.6

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Evonile Pharma, formerly Novartis India, will issue up to 10,287,832 partly paid shares at Rs 860 each, with 5 rights shares offered for every 12 shares held. The issue is worth Rs 8,847.54 million if fully subscribed. The record date is November 11, 2026; applicants must pay Rs 645 per share, with Rs 215 due later. The issue opens November 19 and closes December 3.

Likely market impact

Eligible holders can preserve their stake by subscribing, but must fund Rs 860 per right share. Non-participants may face dilution if fully subscribed.